It's not just the antibodies: Eli Lilly burnishes its second EUA in play with new Covid-19 data on Olumiant plus remdesivir
Eli Lilly is on a roll.
Days after reporting positive data for its Covid-19 neutralizing antibodies, the pharma giant said adding its JAK inhibitor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
